This framework gave us the opportunity to identify, within the so-called “AD continuum”, patients with isolated amyloid pathology (A+) but still no evidence of significant tau pathology (T−) from those showing full-blown AD (A+T+). Here, MAPT is linked to Alzheimer disease.